EUVIMEDEUVIMED entdecken
Leserbrief

COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis

Xiu-Kun Sun iD

Dermatitis® · 2024

DOI: 10.1089/derm.2023.0304 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Dermatitis®, 2024. Verfasst von Xiu-Kun Sun. Beteiligte Einrichtung: Department of Dermatology, Hangzhou Third People's Hospital, Affiliated Hangzhou Dermatology Hospital of Zhejiang University School of Medicine, Hang…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19, Dermatitis, Atopic, Recurrence. Die Arbeit nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCOVID-19Dermatitis, AtopicRecurrenceAdultFemaleHumansMaleMiddle AgedSARS-CoV-2Severity of Illness Index

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Dermatology, Hangzhou Third People's Hospital, Affiliated Hangzhou Dermatology Hospital of Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: Xiu-Kun Sun

Zitieren

APA

Sun, X. K. (2024). COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis. Dermatitis®. https://doi.org/10.1089/derm.2023.0304

Vancouver

Sun XK. COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis. Dermatitis®. 2024. doi:10.1089/derm.2023.0304

BibTeX
@article{Sun2024,
  author = {Sun, Xiu-Kun},
  title = {COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis},
  journal = {Dermatitis®},
  year = {2024},
  doi = {10.1089/derm.2023.0304}
}
Kostenlos starten →